Sonoma Pharmaceuticals
SNOA
13 hedge funds and large institutions have $555K invested in Sonoma Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
22% more capital invested
Capital invested by funds: $456K → $555K (+$99K)
0.18% more ownership
Funds ownership: 0.3% → 0.48% (+0.18%)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
+$178K |
| 2 |
Renaissance Technologies
New York
|
+$61K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$100 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
1
Bard Associates
Chicago,
Illinois
| $262K | +$178K | +1,783 | +145% |
|
|
2
Renaissance Technologies
New York
| $256K | +$61K | +611 | +26% |
|
3
BlackRock
New York
| $15K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $12K | +$1.7K | +17 | +14% |
|
5
Acadian Asset Management
Boston,
Massachusetts
| $6K | – | – | – |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | +$2.49K | +25 | New |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
8
Morgan Stanley
New York
| $1K | – | – | – |
|
|
RE
9
RBC Europe
London,
United Kingdom
| $9 | – | – | – |
|
|
10
Victory Capital Management
San Antonio,
Texas
| – | -$1K | -11 | Closed |
|
|
11
Bank of America
Charlotte,
North Carolina
| – | -$100 | -1 | -25% |
|
SNOA Hedge Fund Activity: Q4 2019 in Review
13 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2019, worth a combined $555K — up 22% from $456K a quarter earlier.
Fund positioning in SNOA was balanced in Q4 2019: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Bard Associates, adding an estimated $178K. The largest seller was Victory Capital Management, exiting entirely with an estimated $1K sold.
- 13 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $555K of Sonoma Pharmaceuticals stock for Q4 2019, up 22% quarter-over-quarter.
- 1 fund opened new Sonoma Pharmaceuticals positions in Q4 2019 and 1 closed out, a net change of 0 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2019 was Bard Associates, an estimated $178K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2019 was Victory Capital Management, an estimated $1K sold.
Based on aggregated 13F filings for Q4 2019.